Physician profile
Ned Snyder
NPI 1568521953
$1,653.09
in general payments reported to CMS, 2019-2025
19 companies · $628 in 2025
The $628 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2021: $156 · 2022: $118 · 2023: $219 · 2024: $308 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,156.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $244.47 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Abbvie INC. | $233.27 | 2019-2025 | Linzess, Viberzi |
| Motiva USA, LLC | $196.20 | 2025 | |
| Medtronic, INC. | $167.81 | 2024-2025 | Nexpowder |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.11 | 2019-2025 | Xifaxan |
| Standard Bariatrics, INC. | $132.20 | 2021 | |
| Ethicon US, LLC | $105.27 | 2019 | |
| Merck Sharp & Dohme LLC | $98.51 | 2023-2024 | Dificid |
| Madrigal Pharmaceuticals | $52.97 | 2025 | Rezdiffra |
| Qol Medical, LLC | $44.65 | 2022-2023 | Sucraid |
| Janssen Biotech, INC. | $36.83 | 2025 | Tremfya |
| Novo Nordisk INC | $34.07 | 2025 | |
| Alcresta Therapeutics, INC. | $25.00 | 2022 | |
| Acelrx Pharmaceuticals, INC. | $24.69 | 2022 | |
| Merz North America, INC. | $24.23 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $24.21 | 2024 | |
| Gilead Sciences, INC. | $17.83 | 2025 | |
| Olympus America INC. | $15.65 | 2019 | |
| Ardelyx, INC. | $14.12 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ned Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.